Company / Gross Profit per Share
Cytek Biosciences, Inc. Gross Profit per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit per Share
$0.81
FY2025
5-year range
$0.75 / $1.66
FY2021-FY2025
Trend
-5.5%
vs FY2024
Sector context
#96 of 99
Health Care
What the data says
Among 99 Health Care companies, Cytek Biosciences, Inc. is in the bottom 3% for gross profit per share. Gross Profit per Share has fluctuated over the past 6 years, ranging from $0.75 in FY2022 to $1.66 in FY2021.
Based on SEC 10-K filings.
0.81 in FY2025 with a 5-year CAGR of -12.5%.
Declined from $0.84 to $0.81 over the past 2 years.
Health Care sector context is included.
Gross Profit per Share over time
Growth rates
- 3-Year CAGR
- +2.5%
- 5-Year CAGR
- -12.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 99This company $0.81 Sector average $13.99
▼
-94.2% below sector average
Key checks
Key Insights
- In FY2025, gross profit per share decreased 5.5% year-over-year.
- Ranks #96 out of 99 companies in the Health Care sector.
- Peak gross profit per share was recorded in FY2021.
- Lowest gross profit per share in the period was in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross Profit per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.81 | -5.5% |
| FY2024 | $0.86 | +2.7% |
| FY2023 | $0.84 | +10.9% |
| FY2022 | $0.75 | -54.4% |
| FY2021 | $1.66 | +4.3% |
| FY2020 | $1.59 | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026